Heidy King-Jones - 01 Sep 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Chief Legal Officer and Corporate Secretary
Signature
/s/ Scott Burrows, by power of attorney
Issuer symbol
SYRE
Transactions as of
01 Sep 2023
Net transactions value
$0
Form type
4
Filing time
05 Sep 2023, 16:15:57 UTC
Previous filing
27 Apr 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Stock Option (Right to Buy) Award $0 +13,495,255 $0.000000 13,495,255 01 Sep 2023 Common Stock 13,495,255 $0.5800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents the right to purchase 13,495,255 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

Chief Legal Officer and Corporate Secretary